PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas

被引：0
|
作者：
Wei Xie
L. Jeffrey Medeiros
Shaoying Li
C. Cameron Yin
Joseph D. Khoury
Jie Xu
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Hematopathology
[2] Baylor College of Medicine,Department of Pathology & Immunology
来源：
Current Hematologic Malignancy Reports | 2020年 / 15卷
关键词：
PD-1; PD-L1; Lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：372 / 381
页数：9
相关论文
共 50 条
  • [31] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    Ansell, Stephen M.
    Lesokhin, Alexander M.
    Borrello, Ivan
    Halwani, Ahmad
    Scott, Emma C.
    Gutierrez, Martin
    Schuster, Stephen J.
    Millenson, Michael M.
    Cattry, Deepika
    Freeman, Gordon J.
    Rodig, Scott J.
    Chapuy, Bjoern
    Ligon, Azra H.
    Zhu, Lili
    Grosso, Joseph F.
    Kim, Su Young
    Timmerman, John M.
    Shipp, Margaret A.
    Armand, Philippe
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04): : 311 - 319
  • [32] PD-L1/PD-L2 genetic profile in the molecular cytogenetic classification of classic Hodgkin lymphoma
    Garcia-Montenegro, Mauro
    Narbaitz, Marina
    Metrebian, Maria Fernanda
    Pavlovsky, Astrid
    Slavutsky, Irma
    VIRCHOWS ARCHIV, 2025,
  • [33] The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma
    Ozturk, Vedia
    Yikilmaz, Aysun Senturk
    Kilicarslan, Aydan
    Bakanay, Sule Mine
    Akinci, Sema
    Dilek, Imdat
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (07): : E375 - E381
  • [34] A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
    Fathima Zumla Cader
    Xihao Hu
    Walter L. Goh
    Kirsty Wienand
    Jing Ouyang
    Elisa Mandato
    Robert Redd
    Lee N. Lawton
    Pei-Hsuan Chen
    Jason L. Weirather
    Ron C. J. Schackmann
    Bo Li
    Wenjiang Ma
    Philippe Armand
    Scott J. Rodig
    Donna Neuberg
    X. Shirley Liu
    Margaret A. Shipp
    Nature Medicine, 2020, 26 : 1468 - 1479
  • [35] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
    Bocanegra, Ana
    Blanco, Ester
    Fernandez-Hinojal, Gonzalo
    Arasanz, Hugo
    Chocarro, Luisa
    Zuazo, Miren
    Morente, Pilar
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 17
  • [36] A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
    Cader, Fathima Zumla
    Hu, Xihao
    Goh, Walter L.
    Wienand, Kirsty
    Ouyang, Jing
    Mandato, Elisa
    Redd, Robert
    Lawton, Lee N.
    Chen, Pei-Hsuan
    Weirather, Jason L.
    Schackmann, Ron C. J.
    Li, Bo
    Ma, Wenjiang
    Armand, Philippe
    Rodig, Scott J.
    Neuberg, Donna
    Liu, X. Shirley
    Shipp, Margaret A.
    NATURE MEDICINE, 2020, 26 (09) : 1468 - 1479
  • [37] PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis
    Ozdemir, Suleyman
    Ton, Ozlem
    Kabukcuoglu, Fevziye
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (04) : 1013 - 1021
  • [38] PD-L1 Is Involved in the Development of Non-Hodgkin's Lymphoma by Mediating Circulating Lymphocyte Apoptosis
    Saber, Manal Mohamed
    VACCINES, 2023, 11 (09)
  • [39] PD-1 Inhibitors Effective in Hodgkin Lymphoma
    不详
    CANCER DISCOVERY, 2015, 5 (02) : 102 - 103
  • [40] A snapshot of the PD-1/PD-L1 pathway
    Ghosh, Chinmoy
    Luong, Gary
    Sun, Yue
    JOURNAL OF CANCER, 2021, 12 (09): : 2735 - 2746
12345